Endometriosis is one of those conditions that takes, on average, eight years to get a diagnosis in the UK. Eight years of being told it’s just bad periods, just stress, just something you need to push through. By the time most women get any kind of formal acknowledgement that something is genuinely wrong, they’ve already tried every painkiller going and possibly a few things they’d rather not mention at a GP appointment. So it’s not surprising that medical cannabis is coming up more frequently in conversations about chronic pelvic pain.
The condition affects roughly 1.5 million women in the UK, and the pain it causes isn’t “just period pain”. It can be constant, debilitating, and for many people it doesn’t respond well to standard treatments. Hormonal therapy helps some people, surgery helps others, but for a significant chunk of people neither option offers enough relief to actually get on with life. That gap is where a lot of interest in cannabis-based medicine has started to grow.
What the Research Actually Shows
The evidence base here is still developing, which is worth being honest about. This isn’t a situation where there are decades of clinical trials to draw on. What exists is a growing body of research into the endocannabinoid system, which is essentially the body’s internal signalling network that helps regulate pain, inflammation, and immune response. Endometrial tissue has been found to contain cannabinoid receptors, and some researchers think disruption to the endocannabinoid system may actually play a role in how the condition develops and how intensely it’s experienced.
For people looking at the specifics of what’s currently understood, there’s a detailed breakdown of medical cannabis for endometriosis from Medicann that covers the research in a fair amount of depth without overselling what’s proven. The honest answer is that the science is promising but not conclusive, and anyone claiming otherwise is either misinformed or trying to sell you something.
What does seem clearer from patient-reported data is that cannabis can be effective for managing chronic pain of the kind endometriosis produces. Studies into cannabis and pain management more broadly suggest it can reduce how intensely pain signals are perceived, which for someone who’s been living in a state of near-constant discomfort is no small thing. Whether it addresses the underlying inflammation in the way some researchers hope is still being worked out.
Getting a Prescription in the UK
Medical cannabis was legalised in the UK in November 2018, but the reality of accessing it on the NHS has been pretty disappointing for most patients. The vast majority of prescriptions are written privately, which does mean there’s a cost involved. Depending on the product and dosage, people are typically looking at somewhere between £100 and £200 a month, though that varies.
The process involves a consultation with a specialist prescriber, a review of your medical history, and a discussion about what you’ve already tried. For endometriosis specifically, prescribers will generally want to see that other treatment options have been explored first. That’s not a barrier designed to be obstructive; it’s just standard medical practice when prescribing anything that still sits outside the usual treatment pathway.
Clinics like Medicann, which operate across Scotland and the wider UK, handle these consultations and can prescribe cannabis-based medicine where it’s clinically appropriate. They’re not the only option, but they are one of the more established ones with a specific focus on conditions involving chronic pain.
The Bigger Picture
There’s something slightly frustrating about the state of endometriosis treatment in general. It’s a condition that’s been chronically under-researched, partly because it was written off for so long as something women just had to manage. Medical cannabis being added to the conversation is interesting, but it’s one piece of something that needs far more investment and attention across the board.
That said, for people who are currently managing severe pain with limited options, having access to a legally prescribed, clinically supervised treatment that might actually help is genuinely significant. It’s not a cure. It’s not presented as one by the clinicians working in this space. But as part of a wider pain management approach, it’s increasingly being taken seriously in a way it wasn’t five years ago, and that’s at least movement in the right direction.